Published in Proc Natl Acad Sci U S A on August 04, 1998
Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia | NCT00418015
Comprehensive Study of Post-surgical Pain After Pectus or Spine Surgery | NCT04031716
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry (2008) 4.91
Tobacco addiction. Lancet (2008) 3.65
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA (2013) 2.34
The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol (2007) 2.22
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol (2007) 2.18
Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci U S A (2006) 2.09
A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry (2010) 2.02
Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav (2008) 2.00
The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci U S A (1999) 1.96
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet (2006) 1.93
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci (2011) 1.74
A quantitative review of ethnic group differences in experimental pain response: do biology, psychology, and culture matter? Pain Med (2012) 1.74
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain (2006) 1.72
Genetic approaches to addiction: genes and alcohol. Addiction (2008) 1.70
Mu opioids and their receptors: evolution of a concept. Pharmacol Rev (2013) 1.66
Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet (2008) 1.59
Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proc Natl Acad Sci U S A (2008) 1.56
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend (2010) 1.55
Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci (2006) 1.54
Mu-opioid receptor (OPRM1) variation, oxytocin levels and maternal attachment in free-ranging rhesus macaques Macaca mulatta. Behav Neurosci (2011) 1.54
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology (2011) 1.50
Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics (2010) 1.46
Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. Biol Psychiatry (2015) 1.44
Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res (2008) 1.43
The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A (1999) 1.41
The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry (2007) 1.41
Stress, alcohol and drug interaction: an update of human research. Addict Biol (2008) 1.40
Genetic vulnerability and susceptibility to substance dependence. Neuron (2011) 1.40
Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. Subst Use Misuse (2010) 1.39
Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A (2006) 1.37
Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. J Abnorm Psychol (2010) 1.37
The genetics of addiction-a translational perspective. Transl Psychiatry (2012) 1.30
Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov (2009) 1.30
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct (2006) 1.28
The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry (2009) 1.28
Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest (2012) 1.26
The genetics of substance dependence. Annu Rev Genomics Hum Genet (2012) 1.25
Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry (2008) 1.25
Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J (2006) 1.24
Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain (2009) 1.24
Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis (2010) 1.23
Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain (2008) 1.22
Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev (2009) 1.18
The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res (2011) 1.18
Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci (2010) 1.16
Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry (2010) 1.14
OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res (2008) 1.12
Subjective response to alcohol among alcohol-dependent individuals: effects of the μ-opioid receptor (OPRM1) gene and alcoholism severity. Alcohol Clin Exp Res (2012) 1.12
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J (2008) 1.11
Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend (2007) 1.10
A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) (2008) 1.10
Genome-wide genetic associations with IFNγ response to smallpox vaccine. Hum Genet (2012) 1.08
Review. Evidence-based treatments of addiction. Philos Trans R Soc Lond B Biol Sci (2008) 1.07
Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci U S A (2009) 1.07
Pain-related effects of trait anger expression: neural substrates and the role of endogenous opioid mechanisms. Neurosci Biobehav Rev (2008) 1.06
A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J (2012) 1.06
Post-transcriptional regulation of opioid receptors in the nervous system. Front Biosci (2004) 1.06
Fronto-striatal functional connectivity during response inhibition in alcohol dependence. Addict Biol (2012) 1.05
Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clin Pharmacol Ther (2010) 1.05
The evolution of vertebrate opioid receptors. Front Biosci (Landmark Ed) (2009) 1.05
Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des (2010) 1.05
Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology (2011) 1.05
The genetics of the opioid system and specific drug addictions. Hum Genet (2012) 1.04
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology (2012) 1.03
Former heroin addicts with or without a history of cocaine dependence are more impulsive than controls. Drug Alcohol Depend (2012) 1.02
Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res (2008) 1.01
Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. Brain Res (2009) 1.01
Role of a functional human gene polymorphism in stress responsivity and addictions. Clin Pharmacol Ther (2008) 1.01
Initial evidence of an association between OPRM1 and adolescent alcohol misuse. Alcohol Clin Exp Res (2009) 1.00
Individualised treatment in alcohol-dependent patients. Eur Arch Psychiatry Clin Neurosci (2010) 1.00
Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr Opin Pharmacol (2009) 0.99
Abnormal pain response in pain-sensitive opiate addicts after prolonged abstinence predicts increased drug craving. Psychopharmacology (Berl) (2009) 0.99
Bidirectional translational research: Progress in understanding addictive diseases. Neuropharmacology (2008) 0.99
A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol (2009) 0.98
Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res (2008) 0.98
Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience (2012) 0.98
A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. Drug Alcohol Depend (2010) 0.98
Role of the HPA axis and the A118G polymorphism of the mu-opioid receptor in stress-induced drinking behavior. Alcohol Alcohol (2009) 0.97
Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. Exp Clin Psychopharmacol (2012) 0.97
Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. Alcohol Alcohol (2009) 0.97
Genetic influences on the dynamics of pain and affect in fibromyalgia. Health Psychol (2010) 0.97
Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol (2012) 0.97
Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS). Mol Neurobiol (2014) 0.96
Genetic contributions to pain: a review of findings in humans. Oral Dis (2008) 0.96
Convergence of genome-wide association and candidate gene studies for alcoholism. Alcohol Clin Exp Res (2012) 0.96
Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. BMC Med Genet (2008) 0.95
Recent advances in the use of opioids for cancer pain. J Pain Res (2009) 0.95
Perioperative analgesic treatment in Latino and non-Latino pediatric patients. J Health Care Poor Underserved (2010) 0.95
Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity. Pain (2012) 0.94
Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology (2014) 0.94
Genes and epigenetic processes as prospective pain targets. Genome Med (2013) 0.93
Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacol Ther (2013) 0.93
Symbiotic relationship of pharmacogenetics and drugs of abuse. AAPS J (2006) 0.93
The genetics of alcohol and other drug dependence. Alcohol Res Health (2008) 0.93
Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav (2009) 0.93
Child μ-opioid receptor gene variant influences parent-child relations. Neuropsychopharmacology (2011) 0.92
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis (1980) 14.25
Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci (1984) 4.87
Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature (1993) 4.81
A potent and selective endogenous agonist for the mu-opiate receptor. Nature (1997) 3.87
Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature (1993) 3.19
A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature (1993) 2.68
Atrial G protein-activated K+ channel: expression cloning and molecular properties. Proc Natl Acad Sci U S A (1993) 2.57
Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol (1993) 2.54
Structure of the adrenergic and related receptors. Annu Rev Neurosci (1989) 2.24
Dual function of the voltage-dependent Ca2+ channel alpha 2 delta subunit in current stimulation and subunit interaction. Neuron (1996) 2.04
Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol (1993) 2.04
Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol (1995) 1.84
Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry (1998) 1.72
Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem (1993) 1.55
Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. J Biol Chem (1991) 1.46
Role of N-linked glycosylation in rat renal Na/Pi-cotransport. J Biol Chem (1994) 1.46
Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett (1994) 1.39
mu opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci U S A (1993) 1.39
Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett (1994) 1.39
Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J (1993) 1.34
Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells. J Biol Chem (1990) 1.30
Differential regulation by cAMP-dependent protein kinase and protein kinase C of the mu opioid receptor coupling to a G protein-activated K+ channel. J Biol Chem (1994) 1.22
The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci (1995) 1.17
Opiates, opioids and addiction. Mol Psychiatry (1996) 1.10
Opiate and cocaine addictions: challenge for pharmacotherapies. Pharmacol Biochem Behav (1997) 1.09
Agonist-induced desensitization of the mu opioid receptor-coupled potassium channel (GIRK1). J Biol Chem (1995) 1.06
Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Neurochem Res (1996) 1.04
ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides (1984) 1.02
Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: a case of naloxone-induced withdrawal. Metabolism (1997) 0.97
Metyrapone-induced withdrawal symptoms. Br J Addict (1990) 0.93
A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci (1986) 0.91
Modulation of CRF-R1 mRNA in rat anterior pituitary by dexamethasone: correlation with POMC mRNA. Peptides (1996) 0.89
Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity. Ann N Y Acad Sci (1982) 0.89
Beta endorphin levels in CSF during methadone maintenance. Life Sci (1987) 0.87
Functional coupling of a mu opioid receptor to G proteins and adenylyl cyclase: modulation by chronic morphine treatment. Addict Biol (1996) 0.85
The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res (2005) 12.94
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 7.30
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 6.73
HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA (1989) 6.68
Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med (1999) 6.21
Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet (1998) 6.04
Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development (1995) 5.18
Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell (1999) 4.83
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax (2008) 4.79
Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes (1996) 4.20
Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res (1993) 4.11
Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology (2012) 4.09
Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science (1997) 4.07
Narcotic blockade. Arch Intern Med (1966) 3.80
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem (2000) 3.49
Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol (1994) 3.46
Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci U S A (2000) 3.41
Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension (1999) 3.33
Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc Natl Acad Sci U S A (2002) 3.29
Identification and characterization of genes that are required for the accelerated degradation of mRNAs containing a premature translational termination codon. Genes Dev (1995) 3.24
Rapid Avr9- and Cf-9 -dependent activation of MAP kinases in tobacco cell cultures and leaves: convergence of resistance gene, elicitor, wound, and salicylate responses. Plant Cell (1999) 3.17
Animal models of Salmonella infections: enteritis versus typhoid fever. Microbes Infect (2001) 3.12
Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med (1998) 3.11
The concepts of 'sameness' and 'difference' in an insect. Nature (2001) 3.08
DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res (2007) 3.07
Honeybee navigation: nature and calibration of the "odometer". Science (2000) 3.06
Activation of a mitogen-activated protein kinase pathway is involved in disease resistance in tobacco. Proc Natl Acad Sci U S A (2001) 2.98
Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med (1986) 2.87
Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int (2006) 2.85
Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol (2012) 2.83
GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A (1999) 2.80
Studies on cytochrome oxidase. Interactions of the cytochrome oxidase protein with phospholipids and cytochrome c. J Biol Chem (1975) 2.80
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol (1994) 2.70
Desensitization of AMPA receptors upon multiquantal neurotransmitter release. Neuron (1993) 2.70
Honeybee dances communicate distances measured by optic flow. Nature (2001) 2.61
Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet (1999) 2.60
X-ray diffraction of actively shortening muscle. Proc Natl Acad Sci U S A (1976) 2.59
T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun (1995) 2.57
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci (2000) 2.55
Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol (1993) 2.54
B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol (1996) 2.53
T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest (1994) 2.51
Comparative anatomy of the human APRT gene and enzyme: nucleotide sequence divergence and conservation of a nonrandom CpG dinucleotide arrangement. Proc Natl Acad Sci U S A (1987) 2.49
Mediation of neuronal apoptosis by enhancement of outward potassium current. Science (1997) 2.47
Nitric oxide and salicylic acid signaling in plant defense. Proc Natl Acad Sci U S A (2000) 2.47
Transmission/disequilibrium tests using multiple tightly linked markers. Am J Hum Genet (2000) 2.45
Comparisons of two methods for haplotype reconstruction and haplotype frequency estimation from population data. Am J Hum Genet (2001) 2.44
Xa21D encodes a receptor-like molecule with a leucine-rich repeat domain that determines race-specific recognition and is subject to adaptive evolution. Plant Cell (1998) 2.43
Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A (1999) 2.42
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther (2004) 2.42
p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene (2001) 2.40
Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol (2000) 2.40
Phylogenetic analysis of rumen bacteria by comparative sequence analysis of cloned 16S rRNA genes. Anaerobe (1998) 2.31
Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol (1998) 2.29
Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human macrophages. J Infect Dis (1999) 2.29
Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain (1995) 2.29
Mammalian homologs of seven in absentia regulate DCC via the ubiquitin-proteasome pathway. Genes Dev (1997) 2.26
Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet (2005) 2.24
Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit. Cell (1996) 2.17
Nucleotide sequence and organization of the mouse adenine phosphoribosyltransferase gene: presence of a coding region common to animal and bacterial phosphoribosyltransferases that has a variable intron/exon arrangement. Proc Natl Acad Sci U S A (1985) 2.17
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun (2008) 2.15
Criminal patients with XYY sex-chromosome complement. Lancet (1966) 2.14
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
X-ray spectra estimation using attenuation measurements from 25 kVp to 18 MV. Med Phys (1999) 2.11
Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom (1991) 2.10
Qualitative semi-parametric test for genetic associations in case-control designs under structured populations. Ann Hum Genet (2003) 2.07
Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol (2000) 2.06
14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J (2000) 2.06
Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol (1994) 2.06
Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet (1999) 2.02
Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav (2008) 2.00
Linker histones are not essential and affect chromatin condensation in vivo. Cell (1995) 1.99
Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell (1995) 1.99
Interleukin 12 at the site of disease in tuberculosis. J Clin Invest (1994) 1.98
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Assignment of the gene for adenine phosphoribosyltransferase to human chromosome 16 by mouse-human somatic cell hybridization. Proc Natl Acad Sci U S A (1974) 1.97
Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther (1994) 1.95
Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development (2001) 1.95
Mitotic recombination is suppressed by chromosomal divergence in hybrids of distantly related mouse strains. Nat Genet (2001) 1.92
RNA expression analysis using an antisense Bacillus subtilis genome array. J Bacteriol (2001) 1.89
Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol (1996) 1.89
Measurement of total body potassium with a shadow shield whole-body counter: calibration and errors. Phys Med Biol (1971) 1.89
The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res (1993) 1.88
Differential dependence on GluR2 expression of three characteristic features of AMPA receptors. J Neurosci (1997) 1.86
Ribosome recycling by ribosome recycling factor (RRF)--an important but overlooked step of protein biosynthesis. Adv Biophys (1996) 1.86
Hydrogenase measurement with photochemically reduced methyl viologen. J Bacteriol (1969) 1.85
Cloning, expression and characterization of a family 48 exocellulase, Cel48A, from Thermobifida fusca. Eur J Biochem (2000) 1.85
Improved dual-energy material discrimination for dual-source CT by means of additional spectral filtration. Med Phys (2009) 1.85
Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol (1996) 1.85
Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol (2008) 1.84
Mutations in the gamma-actin gene (ACTG1) are associated with dominant progressive deafness (DFNA20/26). Am J Hum Genet (2003) 1.83
Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology (2008) 1.80
Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res (2001) 1.78
A new electrophoretic-autoradiographic method for the visual detection of phosphotransferases. Anal Biochem (1973) 1.78
Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia. Neuroscience (2006) 1.78